Background:
To date, optimal agents for low-density lipoprotein
cholesterol (LDL-C) reduction in patients with established atherosclerotic
cardiovascular disease are still being explored. Thus, we evaluated the
efficiency of novel LDL-C-lowering therapies in the secondary prevention of
cardiovascular events.
Methods:
We included randomized clinical trials
(RCTs) that explored the effects of different LDL-C lowering agents including
alirocumab, evolocumab, and bempedoic acid in adult patients with cardiovascular
disease. Several databases were searched from inception through 2022. The safety
endpoint includes new-onset diabetes, serious adverse events, and neurocognitive
disorders with at least 1 year of follow-up. The efficacy outcomes included
composite adverse cardiovascular outcomes, all-cause death, and cardiovascular
death.
Results:
Seven RCTs comprising 53,106 patients were included in
this research. Bempedoic acid ranked first in reducing the risk of new-onset
diabetes (risk ratio [RR] 0.72, 95% credible interval [CrI] 0.52–0.99) and risk
of the composite cardiovascular outcome (RR 0.75, 95% CrI 0.57–0.99).
Meta-regression analysis demonstrated that elevated risk of new-onset diabetes
was positively correlated with a significant reduction in LDL-C levels (
p
=
0.03). All treatment agents were associated with a decreased risk of a
composite adverse cardiovascular outcome.
Conclusions:
The present
analysis showed that bempedoic acid ranked first in reducing the risk of a
composite cardiovascular outcome. In addition, it ranked first in reducing the
risk of new-onset diabetes compared with placebo and evolocumab. Our analysis
also suggests that the increased risk of new-onset diabetes might be associated
with a reduction in LDL-C levels. Besides, the present analysis found that
alirocumab ranked first in decreasing all-cause mortality and cardiovascular
mortality.